Skip to main content
NAMS
NASDAQ Life Sciences

NewAmsterdam Q3 Revenue Jumps to $19.2M; PREVAIL Interim Result Due 1Q2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$20.69
Mkt Cap
$2.379B
52W Low
$19.13
52W High
$42.205
52W Position info
8.2% above low
Off High info
51% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

NAMS is trading near its 52-week low of $19.13 (8.2% above the low).

Summary

NewAmsterdam reported Q3 revenue of $19.2M (vs $0.3M a year ago) and a narrowed $17.4M net loss, with $643.1M in cash. The PREVAIL cardiovascular outcomes interim result is expected in 1Q2027 and RUBENS topline around year-end 2026.


Key Events · Earnings and Guidance · NAMS

  • Q3 Revenue Jumps on Menarini Milestones

    Revenue was $19.2M for the quarter ended September 30, 2026, versus $0.3M a year earlier, primarily from recognition of regulatory milestones under the Menarini license.

  • Net Loss Narrows on Non-Cash Warrant Gain

    Net loss fell to $17.4M from $72.0M, including a $23.1M non-cash fair-value gain on derivative warrant liabilities — a mark-to-market entry, not cash or new dilution.

  • Cash of $643.1M Funds Readouts

    Cash, cash equivalents and marketable securities totaled $643.1M at September 30, 2026, down from $728.9M at December 31, 2025, with $109.6M used in operations over nine months.

  • PREVAIL Interim Result Expected 1Q2027

    The company expects to reach the predefined event number for the PREVAIL interim analysis in 4Q2026, with the result expected in 1Q2027; RUBENS Phase 3 topline is expected around year-end 2026.


Analysis · NAMS · Life Sciences

This is the first top-line print since European approval of obicetrapib, and the headline revenue of $19.2M versus $0.3M a year ago mostly reflects Menarini milestone recognition rather than product sales. The net loss narrowed to $17.4M from $72.0M, largely on a $23.1M non-cash warrant remeasurement gain — an accounting mark, not cash. What matters more is the calendar: PREVAIL, the first CETP outcomes trial in over a decade, hits its event target in 4Q2026 with the result expected 1Q2027, and RUBENS topline lands around year-end 2026. With $643.1M in cash, the company is funded into those readouts, so the binary risk is clinical, not financial.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NAMS was trading at $20.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $19.13 to $42.21. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NAMS - Latest Insights

NAMS
Nov 04, 2026, 7:31 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.24
Real-time Price: $18.32 info
Change: -$1.92 (-9%) info
Market Cap: $2.208B info
NAMS
Sep 29, 2026, 8:22 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.71
Real-time Price: $18.32 info
Change: -$5.39 (-23%) info
Market Cap: $2.208B info
NAMS
Sep 22, 2026, 4:58 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $23.32
Real-time Price: $18.32 info
Change: -$5.00 (-21%) info
Market Cap: $2.208B info
NAMS
Sep 21, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $22.82
Real-time Price: $18.32 info
Change: -$4.50 (-20%) info
Market Cap: $2.208B info
NAMS
Aug 05, 2026, 7:08 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.52
Real-time Price: $18.32 info
Change: -$9.20 (-33%) info
Market Cap: $2.208B info